Articles tagged with Drug Therapy
A new study published in the Canadian Medical Association Journal found that older adults discharged from hospital with a new prescription for sedatives are at increased risk of falls, further need for acute hospital care, and death within 30 days. The study looked at over 1.86 million adults aged 66 years and older and found a 20% hig...
Lecanemab is approved to treat early Alzheimer's disease, but its clinical benefits are modest. The treatment carries serious adverse effects and requires resource-intensive monitoring with MRI scans.
Researchers at Texas A&M University develop a laser technique called TRIP to directly measure quantum forces shaping proteins, enabling accurate prediction of how pharmaceutical drugs interact with them. This breakthrough could lead to the design of medicines tailored to specific diseases, revolutionizing precision medicine.
A new prodrug and localized drug delivery platform have been developed by researchers to selectively target cancer cells. The platform uses carbamate masking of the 4-anilinoquinazoline hinge nitrogen to modulate exposure and enable controlled activation of EGFR-TKIs in tumour microenvironments.
A phase III trial is investigating whether an immune-boosting drug can help keep early-stage lung cancer from coming back after surgery. Researchers aim to enroll 336 participants with stage I non-small cell lung cancer and determine if the treatment reduces recurrence.
Researchers found that women who used hormonal birth control in young adulthood had larger brain volumes in regions vital to memory and cognition. Estrogen exposure throughout life may be beneficial for brain health, particularly in reducing dementia risk. The study suggests hormone therapy during menopause may also support brain health.
Researchers found that pramipexole, a Parkinson's disease medication, improved symptoms of anhedonia in patients with treatment-resistant depression. The therapy was associated with positive effects on the brain's reward system and increased physical activity.
The FDA has accepted Genentech's supplemental Biologic License Application for atezolizumab, supported by phase III ATOMIC trial results. The trial showed a 50% reduction in cancer recurrence or death and 86.3% disease-free survival rate.
A White House announcement on treating autism with leucovorin and against acetaminophen during pregnancy led to significant increases in internet searches for these topics. Nearly 1 million additional searches for leucovorin were recorded, alongside over 4 million searches for acetaminophen.
A new review highlights advances in preventing bone loss in people with rheumatoid arthritis, showing that modern antirheumatic therapies can significantly reduce both localized erosions and generalized bone loss. Emerging imaging technologies like HR-pQCT have been found to detect subtle bone erosions earlier and more sensitively.
Researchers identify key mechanisms and molecular targets to prevent tumor progression in patients with rhabdomyosarcoma, a rare soft tissue cancer affecting young children. Two new treatment possibilities have been highlighted, targeting the IRE1α-XBP1 signaling axis and protein TAK1.
Researchers from Florida Atlantic University have identified a key immune pathway that appears to drive damaging inflammation in Huntington disease. Blocking this pathway reduced brain inflammation, protected neurons, and improved movement in a humanized mouse model of the disease.
Mazdutide, a GLP-1 receptor dual agonist, provides clinically meaningful weight reduction in Chinese adults with obesity. However, gastrointestinal adverse reactions are more common among those taking the drug compared to placebo.
Patients described GLP-1 RA therapy as a facilitator of lifestyle change, highlighting the need for standardized guidelines on patient education and clinical support. The quality of care was highly variable, leading to potential expectation management issues around adverse effects and long-term management.
Researchers have found a widely available drug combination to be an effective treatment for patients with systemically active Sjögren's disease. The combination of leflunomide and hydroxychloroquine reduced disease activity while maintaining a favorable safety profile.
Adding fovinaciclib to first-line aromatase inhibitor therapy confers significant progression-free survival benefits and consistent improvements in efficacy outcomes. The treatment also has manageable safety profiles with no negative impact on quality of life.
A study published in the New England Journal of Medicine shows an investigational targeted therapy, daraxonrasib, significantly extends overall survival for patients with metastatic pancreatic cancer, reducing death risk by 60%, compared to standard chemotherapy.
Researchers found that a vitamin D analog reduced fibroblast activation and increased T cell infiltration in pancreatic tumors, improving chemotherapy responses and progression-free survival. Patients with high vitamin D receptor expression also had longer overall survival.
Researchers developed a senolytic therapy using dasatinib and quercetin, which preserved disc structure and reduced inflammation, highlighting JUN signaling as a key pathway. This preclinical study provides evidence for a potential therapeutic strategy to slow disease progression in individuals with genetic susceptibility.
Researchers used wastewater surveillance to detect drug-resistant Candida auris strains up to five months before patients showed symptoms, opening a new frontier for hospitals. The study found higher detection rates and concentrations of the pathogen in hospital wastewater compared to community-scale treatment plants.
A phase 2 clinical trial found that burosumab safely restored normal phosphate levels and improved physical function in patients with severe fibrous dysplasia. Key findings include reduced pain, fatigue, and mobility impairment, as well as significant improvements in children's mobility and independence.
A USC-led study analyzed insurance claims data from 940 patients with ALK-positive non-small cell lung cancer to compare the effectiveness of five tyrosine kinase inhibitors. The results showed alectinib and lorlatinib as promising treatments, offering longer survival times and better treatment duration compared to other options.
A new study presents dual immunization against respiratory syncytial virus (RSV) using RSVpreF and nirsevimab, showing reduced hospitalizations among infants in France. The study found that this combined approach demonstrates potential for enhanced RSV prevention and protection
A novel antibody, NG101, accelerates the regeneration of damaged spinal cord tissue by neutralizing a protein that blocks nerve fiber growth. This therapy enables new nerve fibers to form functional connections, allowing patients to become more independent and potentially recover arm and hand function.
The ERASur clinical trial is investigating whether total ablative therapy can improve overall survival in patients with newly diagnosed, limited metastatic colorectal cancer. The study has reached one-third patient accrual milestone, signaling strong momentum.
Regular physical activity is essential for mitigating the regain of lost weight after discontinuing GLP-1 medications. Exercise has complementary effects beyond energy balance, including improved insulin sensitivity and increased fat oxidation. Clinicians must develop individualized strategies to improve exercise adherence.
The ASPIRE trial aims to enroll 1,200 participants with advanced prostate cancer and assess the impact of chemotherapy on overall survival and disease progression. Genetic profiling is included to identify patients who benefit most from intensified treatment.
A new study from Karolinska Institutet shows that low doses of endoxifen reduce breast density to the same extent as tamoxifen without causing severe side effects. The results suggest a lower dose may be sufficient for therapeutic effect while being better tolerated.
A new review found that GLP-1 weight-loss drugs significantly reduced the risk of heart attacks, strokes, and premature death. The treatment also lowered rates of non-fatal heart attacks, hospital admissions for heart failure, and deaths from any cause.
Chronic liver disease in the US costs $41.57 billion, with prescription medication expenditures accounting for nearly half of all-cause healthcare expenditures. Poor adherence to antiviral medications is a key factor in preventing disease progression and treatment, with high out-of-pocket costs increasing non-adherence risk.
Researchers from UH, Baylor College of Medicine and MD Anderson Cancer Center propose a new treatment approach for Crohn's disease by targeting the stress signal that fuels inflammation. They found that repurposing two existing cancer medications can promote natural repair and regeneration of the intestinal lining.
A new study shows that while dental opioid prescription fills in the US have dropped by 27% since 2021, the rate remains higher than in other developed countries and the US territory of Puerto Rico. The study suggests that some US dentists are still overprescribing opioids.
A recent study from the University of Eastern Finland found that people with Parkinson's disease are using psychotropics more frequently than controls, even before diagnosis. The use of psychotropic medications increases as the disease progresses, reflecting emerging non-motor symptoms and worsening disease progression.
A new analysis found that prescriptions for curable hepatitis C drugs have declined sharply in recent years, leaving millions without treatment. The researchers urge swift actions to deliver the drugs to those who need them, including increased screening and system-level changes.
A new study by University College London found that gabapentinoids, prescribed for chronic pain, double the risk of hospitalization for drug poisoning when combined with benzodiazepines or opioids. The risk persists even after starting gabapentinoid treatment, suggesting they may not be an effective solution to reduce poisoning risks.
A new Cochrane review of 17 clinical trials found that anti-amyloid Alzheimer's drugs have no significant impact on cognitive decline or dementia severity, but may increase the risk of brain swelling and bleeding. The evidence suggests that these drugs are unlikely to provide clear benefit to patients.
Researchers identified patient-reported symptoms associated with GLP-1s, including menstrual changes, fatigue, and temperature-related complaints, that may not be fully captured in clinical trials or drug labeling. Nearly 4% of Reddit users reported reproductive symptoms, and fatigue was the second most common complaint.
A new analysis from UC San Francisco argues that diagnostics are being overlooked, slowing progress against major diseases despite advances in targeted therapies. The study suggests that nearly half of the world's population lacks adequate access to diagnostics due to inadequate investment and insurance reimbursement.
Researchers at the University of Waterloo have discovered a safer and more effective way to treat Alzheimer's disease by combining anti-amyloid antibodies with molecules found in grapes, berries, peanuts, and turmeric. This combination approach neutralizes amyloid protein clumping in the brain, leading to better outcomes.
Scientists at the University of Virginia Health System have developed a suite of AI-powered tools, called YuelDesign, YuelPocket and YuelBond, to transform how new drugs are created. These tools can design drug molecules tailored to fit their protein targets exactly, even accounting for protein flexibility.
A randomized trial found that duloxetine does not prevent painful neuropathy caused by oxaliplatin-based chemotherapy in patients with stage II or III colorectal cancer. The study suggests that duloxetine should only be used for managing existing neuropathy, not prevention.
The Alliance for Clinical Trials in Oncology is enrolling adolescent and young adult cancer patients in various trials, including genetic services and treatment studies. These trials aim to address longstanding gaps in care and improve outcomes for AYAs with cancer.
In this randomized clinical trial, mirtazapine effectively reduced methamphetamine use in adults with methamphetamine use disorder. The study's findings have important implications for the treatment of this condition, which currently lacks approved pharmacotherapies.
City St George's, University of London, is partnering with Paradigm Biopharmaceuticals to test a potential treatment for osteoarthritis. The partnership aims to investigate the mechanism of action of pentosan polysulfate sodium (iPPS) on bone marrow lesions, which are linked to pain in osteoarthritis.
Researchers identified NOX-1 as a key molecular target to prolong ketamine's therapeutic benefits. Combining ketamine with NOX-1 inhibitors significantly extended its antidepressant-like effects. K-4, a novel AMPAR modulator, also showed rapid antidepressant effects that persisted for at least 2 weeks.
Researchers have identified and overcome metabolic instability as the key barrier to developing ovalicin, a potent relative of fumagillin. Using chem-bio hybrid synthesis, they created metabolically stable drug candidates that worked in animal models of amebiasis.
Early-stage drug development has nearly doubled globally over the past decade, driven by a shift from a US-dominated system to a two-hub structure. This change may have implications for scientific workforce development, investment, and patient access to new therapies.
A Concordia-led study reveals that many Canadian surgery residents scored below the threshold of adequate pain knowledge, with limited grasp of the biopsychosocial model and unpreparedness to treat pain in children. This highlights the need for improved medical training to address this critical gap.
A study found that cancer patients during the last phase of life experienced more bleeding events than thromboembolic events. Most patients continued their antithrombotic therapy despite increased bleeding risk, with over 28% experiencing at least one bleeding episode.